LGBTQI: LGBTQ | Psychology

Research Requirement:

LGBTQ ResponseDiscussion2..docx 2. Bipolar disorder (BD) is a chronic mental health condition that impacts adults of all genders, races, and ages. BD typically presents in late adolescence or early adulthood and is characterized by episodes of mania or hypomania and depression. There are several challenges and unique factors that must be taken into consideration when addressing bipolar within the LGBTQI+ population. The LGBTQI+ population is at higher risk for mental health disorders, to include bipolar disorders. The social isolation, stigma, and stress associated with being within this minority population may interact with genetic and biological predispositions and increase the risk for the presentation of BD. Furthermore, these negative experiences may exacerbate symptoms and influence the progression and management of BD (Gmelin et al., 2022). Bipolar disorder places a high economic burden on the United States. It is estimated that BD results in an estimated $195 billion of lost funds due to direct and indirect costs. Direct cost includes ongoing medical treatment and indirect costs include loss of work or loss of home (Bessonova et al., 2020). The LBGTQI+ population members with mental health disorders experience greater indirect costs than the general population, as this population typically experiences challenges with academics, employment, and housing due to stigma (Chen, Wang, She, Qin, & Ming, 2022).   Diagnosing BD requires a comprehensive assessment that includes a detailed psychiatric history, family history, mood charting, and identification of triggering factors. Psychiatric Mental Health Nurse Practitioner (PMHNP) can use several assessment tools to help screen for BD symptoms, such as the Mood Disorder Questionnaire or the Hamilton Depression Rating Scale (Culpepper, 2014). It is important for providers to be aware these questionaries may not be culturally sensitive to the LGBTQI+ populations, so interpretation should consider cultural context (Chen, Wang, She, Qin, & Ming, 2022).   Treatment of BD within the LBGTQI+ population has greatest success when a combination of pharmacological and nonpharmacological treatment approaches is used. Pharmacological treatment may include mood stabilizers, antipsychotics, and antidepressants. Lithium is a mood stabilizer that acts on the sodium channels and second-messenger systems. Valproate is a mood stabilizer that enhances GABAergic activity. The PMHNP must consider how other medications may impact how these medications are metabolized. Similarly, atypical antipsychotics, such as Aripiprazole, Olanzapine, Quetiapine, can be used to manage manic or mixed episodes. However, the patient must be closely monitored for side effects, such as weight gain, sedation, or metabolic syndrome (Culpepper, 2014).               Nonpharmacological interventions should start with psychoeducation to help patients better understand the disease process and recognize signs and symptoms of mood instability. Additionally, a positive community support system can help members of the LBGTQI+ population better manage the BD disease process. Community support may include support groups for LBGTQI+ members with BD, financial support network, or social support activities. This collaborative approach increases the likelihood that the LBGTQI+ patient will adhere to the treatment plan and ensures that the patient has the support they need to manage their mental health disorder (Moagi et al., 2021). ResponseDiscussion2..docx Response Discussion Introduction to a topic related to LGBTQI behavioral and mental health The mental health of individuals within the LGBTQI community has been a growing area of research in recent years, with increasing attention to the unique challenges faced by these individuals. One significant issue is the experience of trauma, which can include emotional, physical, and sexual abuse, often resulting from discrimination, stigmatization, and marginalization within society. This trauma can lead to a higher risk of developing mental health disorders such as depression, anxiety, substance use disorders, and PTSD (Budge et al., 2013). As a PMHNP, it is important to understand the impact of trauma on the LGBTQI community and apply appropriate assessment and intervention strategies in a culturally competent manner.   Epidemiology and economic costs The LGBTQI population experiences elevated rates of trauma compared to their heterosexual and cisgender counterparts. According to the National LGBTQ Task Force (2021), up to 50% of LGBTQI individuals report experiencing some form of abuse, discrimination, or violence in their lifetime, with transgender individuals being disproportionately affected. Additionally, studies have shown that LGBTQI youth are more likely to experience homelessness due to family rejection, which can expose them to further trauma (Wilson, 2020). The economic costs of trauma in the LGBTQI community are substantial. Mental health disorders resulting from trauma often lead to increased healthcare utilization, disability claims, and lost productivity. The total economic burden of mental health issues, including trauma-related conditions, is estimated to be in the billions annually (CDC, 2021). These costs reflect the need for targeted interventions and the promotion of inclusive care for LGBTQI individuals.   Overview of the assessment and tools to assess/DSM-5 Assessing trauma in the LGBTQI community requires a culturally competent approach. Utilizing the DSM-5 is essential in identifying trauma-related disorders such as PTSD, major depressive disorder, and anxiety disorders. Common assessment tools include the Trauma Symptom Checklist for Children (TSCC) for youth and the PTSD Checklist for adults (PCL-5), which assess trauma symptoms (Briere, 2019). However, when working with LGBTQI individuals, it is important to consider their unique experiences and ensure that the assessment environment is safe and inclusive. The Gender Minority Stress and Resilience Scale (GMSRS) is another tool that can assess the psychological effects of gender-related discrimination and stress (Budge et al., 2013). When assessing LGBTQI clients, the PMHNP should ask open-ended questions, using language that is affirming and respectful of their gender identity and sexual orientation.   Pharmacological interventions with specifics to dynamics, kinetics, contraindications, side effects, and so on Pharmacological treatment for trauma-related mental health issues in the LGBTQI community is similar to the general population but may require specific considerations. First-line pharmacological interventions for PTSD, anxiety, and depression include SSRIs such as sertraline (Zoloft) and paroxetine (Paxil), which have shown efficacy in treating trauma-related disorders (Davidson et al., 2018). However, PMHNPs must be aware of potential side effects, including sexual dysfunction, which can be particularly relevant in the LGBTQI population, where sexual health and expression are key aspects of well-being (Friedman et al., 2020). Furthermore, for individuals with gender dysphoria or those transitioning, the pharmacological approach may include gender-affirming hormone therapy (e.g., testosterone or estrogen) and/or medications to mitigate mental health symptoms associated with gender transition (Wylie et al., 2021). Contraindications for SSRIs may include a history of serotonin syndrome or certain cardiovascular conditions and side effects like weight gain or insomnia should be monitored closely.   Plan of care to include collaborative interventions and psychotherapeutic options A comprehensive plan of care for LGBTQI individuals with trauma should be holistic, involving both pharmacological and psychotherapeutic interventions. Collaborative care should include a multidisciplinary team consisting of a PMHNP, primary care providers, social workers, and LGBTQI support groups. CBT has been shown to be effective for trauma, particularly in addressing negative thought patterns and behaviors (Cuijpers et al., 2016). Additionally, trauma-focused therapies such as Eye Movement Desensitization and Reprocessing may be particularly effective in reducing PTSD symptoms (Bisson et al., 2019). Psychotherapy should be affirming, non-judgmental, and designed to promote resilience, self-acceptance, and coping mechanisms. Social support networks and community resources that cater specifically to LGBTQI individuals should be incorporated into the treatment plan to ensure comprehensive care. 2. Bipolar disorder (BD) is a chronic mental health condition that impacts adults of all genders, races, and ages. BD typically presents in late adolescence or early adulthood and is characterized by episodes of mania or hypomania and depression. There are several challenges and unique factors that must be taken into consideration when addressing bipolar within the LGBTQI+ population. The LGBTQI+ population is at higher risk for mental health disorders, to include bipolar disorders. The social isolation, stigma, and stress associated with being within this minority population may interact with genetic and biological predispositions and increase the risk for the presentation of BD. Furthermore, these negative experiences may exacerbate symptoms and influence the progression and management of BD (Gmelin et al., 2022). Bipolar disorder places a high economic burden on the United States. It is estimated that BD results in an estimated $195 billion of lost funds due to direct and indirect costs. Direct cost includes ongoing medical treatment and indirect costs include loss of work or loss of home (Bessonova et al., 2020). The LBGTQI+ population members with mental health disorders experience greater indirect costs than the general population, as this population typically experiences challenges with academics, employment, and housing due to stigma (Chen, Wang, She, Qin, & Ming, 2022).   Diagnosing BD requires a comprehensive assessment that includes a detailed psychiatric history, family history, mood charting, and identification of triggering factors. Psychiatric Mental Health Nurse Practitioner (PMHNP) can use several assessment tools to help screen for BD symptoms, such as the Mood Disorder Questionnaire or the Hamilton Depression Rating Scale (Culpepper, 2014). It is important for providers to be aware these questionaries may not be culturally sensitive to the LGBTQI+ populations, so interpretation should consider cultural context (Chen, Wang, She, Qin, & Ming, 2022).   Treatment of BD within the LBGTQI+ population has greatest success when a combination of pharmacological and nonpharmacological treatment approaches is used. Pharmacological treatment may include mood stabilizers, antipsychotics, and antidepressants. Lithium is a mood stabilizer that acts on the sodium channels and second-messenger systems. Valproate is a mood stabilizer that enhances GABAergic activity. The PMHNP must consider how other medications may impact how these medications are metabolized. Similarly, atypical antipsychotics, such as Aripiprazole, Olanzapine, Quetiapine, can be used to manage manic or mixed episodes. However, the patient must be closely monitored for side effects, such as weight gain, sedation, or metabolic syndrome (Culpepper, 2014).               Nonpharmacological interventions should start with psychoeducation to help patients better understand the disease process and recognize signs and symptoms of mood instability. Additionally, a positive community support system can help members of the LBGTQI+ population better manage the BD disease process. Community support may include support groups for LBGTQI+ members with BD, financial support network, or social support activities. This collaborative approach increases the likelihood that the LBGTQI+ patient will adhere to the treatment plan and ensures that the patient has the support they need to manage their mental health disorder (Moagi et al., 2021).